Comparative Pharmacology
Head-to-head clinical analysis: CODAMINE versus ROXICET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CODAMINE versus ROXICET.
CODAMINE vs ROXICET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. It is a prodrug converted to morphine via CYP2D6.
Roxicet is a combination of oxycodone, a full mu-opioid receptor agonist, and acetaminophen, which inhibits cyclooxygenase (COX) enzymes, primarily in the central nervous system, to reduce pain perception and fever.
Adults: 1-2 tablets (codeine 30 mg + acetaminophen 500 mg per tablet) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
1-2 tablets (oxycodone 5-10 mg/acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum acetaminophen 4000 mg/day (3000 mg/day in high-risk patients).
None Documented
None Documented
Terminal elimination half-life: 4–6 hours in adults; prolonged to 8–12 hours in renal impairment (CrCl <30 mL/min)
Oxycodone: 3-5 hours (immediate-release); prolonged in hepatic/renal impairment. Acetaminophen: 2-3 hours.
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% other
Primarily renal (90% as glucuronide conjugates, <10% unchanged). Biliary/fecal excretion is minor (<5%).
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination